Navigation Links
'Seena' clinical trials named for pancreatic cancer advocate
Date:12/1/2011

all drugs combined. Patients will be given this treatment for a maximum of 6 months.
  • In the third treatment, the patient's tumor will be biopsied and analyzed using molecular profiling to determine the next most appropriate treatment. Patients also will receive a drug called Metformin during this part of the study.

    The plan is to attack all components of the cancer: the tumor cell, their support structure and their energy source.

    The clinical trial sites includes the Virginia G. Piper Cancer Center Clinical Trials, a partnership of TGen and Scottsdale Healthcare, where the principal investigator is TGen Physician-In-Chief Dr. Daniel Von Hoff, one of the world's leading authorities on pancreatic cancer. Dr. Von Hoff also is chief scientific officer at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

    Dr. Von Hoff said that TGen, through the Virginia G. Piper Cancer Center at Scottsdale Healthcare and its other PCRT partners, are making progress in the quest to end this cancer: "We are to deliver a knockout punch by combining the best treatments we have against the disease. The contributions of Roger Magowitz represent significant acceleration toward our goal of finding better treatments, and ultimately a cure."

    The other clinical trial sites are:

    Virginia Piper Cancer Institute, Minneapolis, Minn., where the principal investigator is Dr. John Seng: "We are one of the nation's leading pancreatic cancer treatment centers. The new Seena clinical trial will allow patients to take a more active role in their health care, gain access to new drugs, treatments and disease management practices, and contribute to medical research."

    Evergreen Hematology & Oncology, Spokane, Wash., where the principal investigator is Dr. Stephen Anthony: "As the former Chief Medical Officer of TGen Drug Development, I know how meticulously this study will be organized and conducted, using every efficiency possi
    '/>"/>


  • Contact: Steve Yozwiak
    syozwiak@tgen.org
    602-343-8704
    The Translational Genomics Research Institute
    Source:Eurekalert

    Page: 1 2 3

    Related biology news :

    1. Vaccine targeting latent TB enters clinical testing
    2. Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy
    3. BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS
    4. Heart rate recovery predicts clinical worsening in pulmonary hypertension
    5. Worlds first stem cell bandage in human clinical trials
    6. Combination therapy shows potent tumor growth inhibition in preclinical studies
    7. CBIs Interactive Response Technologies for Clinical Trials - the Only IVR/IWR Event of Its Kind - Will Be in Philadelphia on November 14-15, 2011
    8. Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use
    9. Professor Peter J. Coffeys stem cell therapy for Age-Related Macular Degeneration expected to begin clinical trials in 2012
    10. AMIA advises FDA on clinical decision support
    11. Reports highlight the evolving role of clinical microbiology laboratories
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... presented at the 29th Annual International Papillomavirus Conference ... Therapeutics Inc. combats three types of human papillomavirus, ... all cervical cancer. , When tested in several ... of HPV-16, HPV-18 and HPV-11 cells, according to ... who presented the findings at the Seattle conference. ...
    (Date:8/22/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Grant Writing Seminar & Practical Exercises Workshop which will ... Maryland from August 25-26, 2014. These awards are ... research scientists from underrepresented groups in the the FASEB ... year MARC conferred 11 awards totaling $20,350. , The ...
    (Date:8/22/2014)... German . ... are fixated in a way so as to align ... and Fudan University researchers are planning on looking into ... findings are being published today in the scientific journal ... sensitive molecules. Everyone knows that at least from ...
    Breaking Biology News(10 mins):Proteins: New class of materials discovered 2
    ... disease or muscle loss that direct the body to ... a weakened condition. That,s not hard to do thanks ... developed an organic substance that attracts and supports cells ... into problem areas. This development, published online in ...
    ... (ACS) News Service Weekly PressPac with news from ACS, 34 ... the individual journal or the American Chemical Society as the ... RELEASE Clothing to crow about: Chicken feather suits ... may snuggle up in warm, cozy sweats made of chicken ...
    ... Using new technologies that make it easier to sequence ... Comprehensive Cancer Center have identified a series of genes ... each other. These recurrent gene fusions are thought to ... develop. The gene fusions discovered could potentially serve ...
    Cached Biology News:'Smart scaffolds' may help heal broken hearts 2American Chemical Society's Weekly PressPac -- Jan. 7, 2009 2American Chemical Society's Weekly PressPac -- Jan. 7, 2009 3American Chemical Society's Weekly PressPac -- Jan. 7, 2009 4American Chemical Society's Weekly PressPac -- Jan. 7, 2009 5American Chemical Society's Weekly PressPac -- Jan. 7, 2009 6American Chemical Society's Weekly PressPac -- Jan. 7, 2009 7American Chemical Society's Weekly PressPac -- Jan. 7, 2009 8American Chemical Society's Weekly PressPac -- Jan. 7, 2009 9U-M researchers discover new genes that fuse in cancer 2
    (Date:8/22/2014)... Canada (PRWEB) August 22, 2014 ... in model organisms can be accelerated by exome ... and manufacturing technologies, the custom SeqCap EZ Developer ... research. , Mr. Watson will additionally present how ... with commercially available human and mouse exome kits. ...
    (Date:8/21/2014)... research group at the Institute for Molecular Medicine ... Stockholm, has developed a novel "man and machine" ... innovative diagnostic aid was described in PLOS ... method is based on computer vision algorithms similar ... with visualization of only the diagnostically most relevant ...
    (Date:8/21/2014)... 2014 His Majesty Willem-Alexander, King of ... Court of His Majesty Willem-Alexander, King of the Netherlands, ... Opening of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol ... The King will take part in the Grand Opening ... 11 a.m.-12:20 p.m. and tour the plant. POET-DSM is ...
    (Date:8/21/2014)... Mathematic studies at the Program for Evolutionary Dynamics ... Jeffrey Epstein VI Foundation , have shown that the ... elimination. These aggressive cells are the driver mutations that drive ... of what to look for when examining tumors, comes at ... can be extracted from biopsy, it,s very difficult to know ...
    Breaking Biology Technology:Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2
    ... 2011 Landauer, Inc. (NYSE: LDR ... monitoring and the leading domestic provider of outsourced medical physics ... quarter ended March 31, 2011.   Fiscal 2011 ... to $32.3 million on contribution from Medical Physics segment and ...
    ... N.J., May 3, 2011 BioNeutral Group, Inc. ... today announced that it has signed on to ... disinfectant technology to the infection control professionals attending ... in Infection Control and Epidemiology) ( www.apic.org ). ...
    ... Inc. (Nasdaq: VVUS ), a biopharmaceutical company dedicated to ... financial results for the first quarter ended March 31, 2011. ... 2011, VIVUS reported a net loss of $9.9 million or $0.12 ... or $0.23 per share for the first quarter of 2010. The ...
    Cached Biology Technology:Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 12BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 2BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 3BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 4VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
    Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Request Info...
    ... Goat anti-Human Alpha 1 Acid ... azide Goats were immunized ... glycoprotein in Freund's adjuvant. ... absorbed to ensure specificity. ...
    Purified Mouse anti-Hu p120 Catenin (pT916) Storage Temperature: Refrigerate(2 to 8C)...
    Biology Products: